Administration of S1PR2 and ROCK1 antagonists was found to reduce the expression of CD86 and MCP-1 in an acute DSS model of colitis, suggesting that S1PR2 promotes polarization of macrophages to an M1/pro-inflammatory phenotype. The gene discussed is S1PR2; the disease is colitis.